FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial. PMID 40474841 · Br J Surg · 2025-May-31 The study is a randomized phase III trial in oncology with drug interventions, but the abstract does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier curves, or HR). The efficacy endpoints mentioned are TIL-IMP manufacture failure rates and response rates (objective response), which are categorical outcomes, not time-to-event endpoints. Therefore, it does not meet the requirement for a time-to-event efficacy endpoint for inclusion in the Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| WITHDRAWN: Personalized bevacizumab dosing in metastatic colorectal cancer: Statistical considerations for a phase III randomized trial. PMID 40451669 · Dig Liver Dis · 2025-May-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Design of a Patient-Centered Hierarchal Composite Outcome for a Multi-Center Randomized Controlled Trial in Metastatic Bone Disease. PMID 40558261 · Curr Oncol · 2025-May-30 The record describes the design and outcome development for a randomized controlled trial (PERFORM), but it does not report the results of a completed Phase III or Phase II/III trial. The primary outcomes identified are composite and include mortality, physical function, and days at home, but there are no results reported for these endpoints (no KM curves, HRs, etc.). The study is explicitly a protocol/design paper for an ongoing trial, not an original result report. Furthermore, the intervention is surgical (reconstruction vs. fixation), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy of combined lateral and anterior quadratus lumborum blocks in postoperative pain management following pelvic tumor resection: a randomized controlled trial. PMID 40442734 · J Orthop Surg Res · 2025-May-29 The study is a randomized controlled trial in oncology patients (pelvic tumor resection) but it is not a drug-containing intervention trial for a systemic oncology therapy. The intervention is a regional anesthetic nerve block (Quadratus lumborum block) for postoperative pain management. There is no specified trial phase (Phase III/IIIb or Phase II/III), and the primary endpoints are postoperative pain scores, opioid consumption, and recovery quality—none of which are the required time-to-event efficacy endpoints (OS, PFS, etc.) with Kaplan-Meier or HR analysis for an oncology drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A pragmatic, multicenter, randomized trial comparing morning versus evening dosing of adjuvant endocrine therapy (REaCT-CHRONO Study). PMID 40442096 · NPJ Breast Cancer · 2025-May-29 The study is a randomized, drug-intervention trial in oncology (breast cancer) reporting original primary results. However, it is excluded because it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as a primary or key secondary outcome. The primary endpoint is toxicity/tolerability (FACT-ES score), and secondary endpoints are toxicity, QoL, and adherence. Furthermore, the phase is not explicitly established as Phase III or IIIb; it is described as a 'pragmatic, multicenter, randomized trial' without a specified phase. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. PMID 40009498 · Blood · 2025-May-29 The record describes a randomized trial of a drug combination (venetoclax + decitabine) versus intensive chemotherapy in young patients with AML. It reports primary efficacy (CRc rate) and safety, but also includes time-to-event outcomes (overall survival and progression-free survival). The publication type is 'Randomized Controlled Trial' and the trial is registered, indicating a definitive Phase III trial. While the abstract emphasizes response rates, the inclusion of OS/PFS endpoints and the randomized design meet the criteria for eligibility. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Robot-assisted versus video-assisted thoracoscopic thymectomy for stage I-II thymic epithelial tumour: a protocol for the first multicentre, randomised controlled clinical trial. PMID 40441770 · BMJ Open · 2025-May-28 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study. PMID 40436447 · BMJ Open · 2025-May-27 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation. PMID 40421698 · Cochrane Database Syst Rev · 2025-May-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety run-in and part 1 of GIMEMA AML1718: venetoclax combined with FLAI as induction treatment in non-low-risk AML. PMID 40048742 · Blood Adv · 2025-May-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. PMID 39908481 · Blood Adv · 2025-May-27 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Accelerometer measurement error in a randomized physical activity intervention trial in breast cancer survivors was nondifferential but attenuated the intervention effect. PMID 40420153 · Int J Behav Nutr Phys Act · 2025-May-26 This is an original randomized trial report in breast cancer survivors. However, it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention, and its primary efficacy endpoint (change in physical activity energy expenditure) is not a time-to-event outcome like OS, PFS, or DFS, nor does it involve Kaplan-Meier analysis or hazard ratios. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect of intravenous lidocaine on postoperative fatigue syndrome in patients undergoing laparoscopic radical colorectal cancer surgery: a randomized clinical trial. PMID 40415064 · Sci Rep · 2025-May-25 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of combining tislelizumab with capecitabine compared to capecitabine alone in the adjuvant treatment of biliary tract cancers: rationale and protocol design for a randomized clinical trial. PMID 40414848 · BMC Cancer · 2025-May-25 The record is a protocol for a randomized trial, not an original result report of a completed trial. The deterministic review correctly identified it as a 'protocol_without_results', but the metadata's phase is unclear and it is not an original result report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Prostate cancer-Exercise and Metformin randomised controlled feasibility Trial (Pre-EMpT) in men following active surveillance, radical prostatectomy and radiotherapy. PMID 40413550 · Pilot Feasibility Stud · 2025-May-24 The study is a Phase II feasibility trial (not definitive Phase III/IIIb or Phase II/III) and lacks a primary or key secondary time-to-event efficacy endpoint; it focuses on feasibility outcomes. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial. PMID 40413023 · J Immunother Cancer · 2025-May-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Proof-of-Concept Clinical Trial Design for Evolutionary Guided Precision Medicine for Cancer. PMID 40661270 · medRxiv · 2025-May-23 This is a proof-of-concept clinical trial design and simulation study (a protocol/methodological paper) for a novel precision medicine strategy. It does not report results from an actual Phase III or definitive randomized trial with a drug intervention and a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Early mobilization in postoperative glioma patients real world impact on recovery and long term prognosis. PMID 40410289 · Sci Rep · 2025-May-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Staged Turnbull-Cutait pull-through anastomosis comparing with direct anastomosis plus prophylactic ileostomy in the treatment of low rectal cancer after internal sphincter resection (STAR-TAR): study protocol for a randomized controlled trial. PMID 40405283 · Trials · 2025-May-22 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Pancreatic resection with perioperative drug repurposing of propranolol and etodolac - the phase II randomized controlled PROSPER trial. PMID 40402347 · Langenbecks Arch Surg · 2025-May-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Rapid Reduction of Pro-Inflammatory Cytokines with an Oral Topical Composition Comprising Olive Oil, Trimethylglycine and Xylitol: A Randomized Double-Blind Controlled Trial. PMID 40430061 · Int J Mol Sci · 2025-May-21 The study is a randomized, double-blind, controlled trial in human subjects with an original result report. However, it is not an oncology study (investigates periodontitis and obesity), does not involve a drug intervention (tests a topical composition of olive oil, trimethylglycine, and xylitol in toothpaste), and does not have a primary time-to-event efficacy endpoint (primary outcomes are salivary cytokine levels, not OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Associations of pretreatment emotional distress with adherence to therapy for patients with locally advanced rectal cancer: a post hoc analysis of the Chinese FOWARC phase 3 randomized clinical trial. PMID 40399932 · BMC Med · 2025-May-21 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Psychometric validation of the EORTC QLQ-OES18 in patients with advanced or metastatic esophageal squamous cell carcinoma. PMID 40397297 · J Patient Rep Outcomes · 2025-May-21 The study is a psychometric validation of a patient-reported outcome measure (QoL) within a Phase III randomized trial; it does not report primary or key secondary time-to-event efficacy outcomes (OS, PFS, etc.) with Kaplan-Meier or HR. Therefore, it is excluded. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccines for preventing infections in adults with haematological malignancies. PMID 40396505 · Cochrane Database Syst Rev · 2025-May-21 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials. PMID 40398388 · Cell Rep Med · 2025-May-20 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Adjuvant nonavalent HPV vaccination in women treated for vulvar HSIL, a randomized placebo-controlled trial; VulVaccin study protocol. PMID 40394508 · BMC Cancer · 2025-May-20 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Microultrasonography-Guided vs MRI-Guided Biopsy for Prostate Cancer Diagnosis: The OPTIMUM Randomized Clinical Trial. PMID 40121537 · JAMA · 2025-May-20 Eligible as a human oncology randomized Phase III trial with a primary result, but excluded because the intervention is a diagnostic procedure (biopsy method), not a drug, and the primary endpoint is detection rate (diagnostic accuracy), not a time-to-event efficacy outcome. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Interprofessional Team-Based Whole-Course Enteral Nutrition in the Peri-Radiation Therapy Period for Esophageal Cancer. PMID 40401829 · Clin J Oncol Nurs · 2025-May-19 The study is a randomized trial on esophageal cancer reporting time-to-event outcomes (1-year PFS and OS), but it is not a Phase III/IIIb or Phase II/III trial (phase is unclear from metadata) and involves a non-drug intervention (enteral nutrition), not a drug-containing intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy of synbiotic mouthwash on salivary TLR2 levels and oral mucositis in head and neck cancer patients undergoing radiotherapy: a randomized clinical trial. PMID 40389723 · Support Care Cancer · 2025-May-19 The study is a randomized trial in oncology patients but fails eligibility due to: 1) Lack of explicit Phase III/IIIb or Phase II/III designation (metadata unclear, cannot assume). 2) Intervention is a synbiotic mouthwash (a probiotic/device), not a 'drug' per the criteria's exclusion of non-drug-only interventions. 3) Primary endpoint (oral mucositis severity/progression) is a toxicity/safety measure, not a time-to-event efficacy endpoint like OS, PFS, or DFS. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Primary prevention of cardiotoxicity in cancer patients treated with fluoropyrimidines: a randomized controlled trial. PMID 40382663 · Cardiooncology · 2025-May-17 The record describes a randomized trial in cancer patients with a drug intervention (fluoropyrimidines) and a primary time-to-event endpoint (composite including all-cause mortality, analyzed via Kaplan-Meier). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the abstract or metadata; it appears to be a Phase II or earlier trial based on its single-center design, sample size, and focus on prevention rather than definitive efficacy comparison. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical application of trastuzumab and docetaxel in the chemotherapy of human epidermal growth factor receptor 2 positive breast cancer patients. PMID 40391840 · Afr J Reprod Health · 2025-May-16 The study is a randomized trial of trastuzumab and docetaxel in HER2+ breast cancer, but the abstract does not explicitly report a primary time-to-event efficacy endpoint (e.g., OS, PFS) with a Kaplan-Meier curve, hazard ratio, or equivalent survival analysis. 'Longer survival time' is mentioned but is vague and not formally reported as a primary time-to-event endpoint. Phase is not explicitly stated (likely Phase II/III based on design but not confirmed). |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| DeintensiF: Standard versus individualized deintensified follow-up after curative treatment in head and neck cancer: protocol of a randomized pilot study. PMID 40380278 · Pilot Feasibility Stud · 2025-May-16 The record is a protocol for a randomized pilot study comparing follow-up strategies (not a drug intervention) in head and neck cancer. It is not a Phase III/IIIb trial, does not report results, and lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A CT-based intratumoral and peritumoral radiomics nomogram for postoperative recurrence risk stratification in localized clear cell renal cell carcinoma. PMID 40380110 · BMC Med Imaging · 2025-May-16 The study is an oncology, human, randomized study with time-to-event endpoints, but it is a diagnostic/prognostic model development and validation study, not a randomized trial of a drug-containing intervention. It lacks a drug intervention arm and does not test the efficacy of a therapeutic agent. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Perioperative nivolumab and chemotherapy in locally advanced squamous cell carcinoma of the oesophagus: a randomized multicentre phase 2 study with circulating tumor DNA dynamics monitoring. PMID 40375301 · Mol Cancer · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial. PMID 40374694 · Sci Rep · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Anlotinib in combination with docetaxel for advanced nonsmall cell lung cancer after failure of platinum-based treatment: A phase 1/2 trial. PMID 40366884 · Cancer · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial. PMID 40293268 · Clin Cancer Res · 2025-May-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer. PMID 40222201 · Eur J Cancer · 2025-May-15 The record is an exploratory subgroup analysis of the randomized FIRE-3 study, not the primary trial report. While the underlying study is randomized and oncologic, the phase of the trial is not explicitly confirmed in this record. The report type is 'subgroup' as it analyzes a molecularly defined subset. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| PERK+ Macrophages Drive Immunotherapy Resistance in Lymph Node Metastases of Oral Squamous Cell Carcinoma. PMID 40036693 · Clin Cancer Res · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. PMID 39560182 · Neuro Oncol · 2025-May-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: long-term results of a randomized controlled trial. PMID 40369294 · Int J Colorectal Dis · 2025-May-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Partial Breast Reirradiation for Breast Cancer Recurrences After Repeat Breast-Conserving Surgery with Proton Beam Therapy: The Prospective BREAST Trial (NCT06954623). PMID 40429411 · J Clin Med · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma. PMID 39951620 · Blood Adv · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia. PMID 39928953 · Blood Adv · 2025-May-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Probiotic reduces vaginal HPV abundance, improves immunity and quality of life in HPV-positive women: a randomised, placebo-controlled and double-blind study. PMID 40360161 · Benef Microbes · 2025-May-12 The study is randomized and phase-definitive but lacks a drug intervention and a time-to-event efficacy endpoint. It is a probiotic trial for HPV infection, not a cancer treatment trial. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial. PMID 40350430 · Breast Cancer Res · 2025-May-12 This is a randomized window-of-opportunity trial assessing biological effects (TILs, proliferation, apoptosis) of denosumab in early breast cancer, not a Phase II/III or III trial with a primary or key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study. PMID 40350200 · RMD Open · 2025-May-11 The record describes a Phase III randomized trial of a drug (upadacitinib) for rheumatoid arthritis, which is not an oncology condition. No time-to-event efficacy endpoints are reported. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Juntas Contra el Virus del Papiloma Humano: protocol for a pilot randomized controlled trial of an HPV self-sampling intervention for underscreened Latinas. PMID 40349085 · Pilot Feasibility Stud · 2025-May-10 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Frequency and Clinical Significance of Clonal and Subclonal Driver Mutations in High-Risk Neuroblastoma at Diagnosis: A Children's Oncology Group Study. PMID 40036726 · J Clin Oncol · 2025-May-10 The record describes a biomarker analysis (clonal/subclonal mutations) within a Phase III neuroblastoma trial. While it meets criteria for oncology, human, randomized trial, Phase III, and time-to-event endpoints, it does not include a drug-containing intervention as the subject of analysis. The study is a prognostic analysis, not the primary report of the trial's drug intervention efficacy. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Resection and partial liver transplantation from deceased donors with delayed total hepatectomy (RAPID procedure) for hepatocellular carcinoma: a national, multicenter, non-randomized, prospective trial. PMID 40346479 · BMC Cancer · 2025-May-09 The record describes a protocol for a non-randomized, surgical (non-drug) trial in HCC with no time-to-event efficacy results. It fails multiple key eligibility criteria: randomization, drug intervention, definitive phase, time-to-event endpoints, and original results. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |